Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Syndax Pharmaceuticals, Inc. (SNDX : NSDQ)

• Company Description    Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. Number of Employees: 270

• Price / Volume Information    Yesterday's Closing Price: $8.73 Daily Weekly Monthly 20 Day Moving Average: 1,675,642 shares Shares Outstanding: 86.05 (millions) Market Capitalization: $751.19 (millions) Beta: 0.70 52 Week High: $25.07 52 Week Low: $8.58 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.28% -24.11% 12 Week -22.33% -32.60% Year To Date -33.96% -37.66%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 730 Third Avenue 9th Floor - New York,NY 10017 USA ph: 781-419-1400 fax: 781-419-1420 ir@syndax.com http://www.syndax.com

• General Corporate Information    Officers Michael A. Metzger - Chief Executive Officer and Director Dennis G. Podlesak - Chairman Keith A. Goldan - Chief Financial Officer Martin H. Huber - Director Jennifer Jarrett - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87164F105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/07/25 Share - Related Items Shares Outstanding: 86.05 Most Recent Split Date: (:1) Beta: 0.70 Market Capitalization: $751.19 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.81 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.61 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 25.79% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/07/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.49 Price/Cash Flow: - Price / Sales: 17.18 EPS Growth vs. Year Ago Period: -15.29% vs. Previous Quarter: 10.91% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 160.96% ROE 06/30/25 - - 03/31/25 - -101.60 12/31/24 - -80.66 ROA 06/30/25 - - 03/31/25 - -58.41 12/31/24 - -58.74 Current Ratio 06/30/25 - - 03/31/25 - 5.80 12/31/24 - 5.82 Quick Ratio 06/30/25 - - 03/31/25 - 5.75 12/31/24 - 5.82 Operating Margin 06/30/25 - - 03/31/25 - -757.53 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - -757.53 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -757.52 12/31/24 - -1,346.11 Book Value 06/30/25 - - 03/31/25 - 2.50 12/31/24 - 3.38 Inventory Turnover 06/30/25 - - 03/31/25 - 1.36 12/31/24 - 9.03 Debt-to-Equity 06/30/25 - - 03/31/25 - 1.53 12/31/24 - 1.15 Debt-to-Capital 06/30/25 - - 03/31/25 - 60.52 12/31/24 - 53.51

Powered by Zacks Investment Research ©